NEW YORK ( TheStreet) -- What's the deal with Alexion Pharmaceutical (ALXN - Get Report) -- literally? TheStreet's Jim Cramer and "Mad Money" Research Director Nicole Urken discussed what traders can expect from the drastic acquisition talk surrounding the pharma company.While the M&A prospects for the broader markets have seemed rather dull this year, biotech has been red hot, with huge acquisitions lighting up the financial headlines throughout 2013.
Cramer Quick Take: Why Alexion Is Ripe for a Deal
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.